February 21st 2025, 10:00pm
An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its role in guiding targeted treatments.
February 20th 2025, 5:00pm
Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a vaccine.
February 20th 2025, 4:00pm
Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.
February 19th 2025, 5:00pm
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
February 18th 2025, 5:00pm
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
February 17th 2025, 10:00pm
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
February 17th 2025, 5:00pm
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
February 16th 2025, 7:00pm
There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.
February 14th 2025, 10:00pm
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression.
February 13th 2025, 9:35pm
Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at the 2025 ASCO GU meeting.
The Importance of Genetic Testing in Metastatic Colorectal Cancer
Brukinsa Shows Favorable Safety Profile Over Imbruvica in CLL
Cancer is Hard Enough Without Infections
How Patients With Cancer Can Avoid Counterfeit Therapeutics Online